{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:04:16Z","timestamp":1790661856127,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovarian syndrome (PCOS) is a disease that is not limited to reproductive symptoms; it is also significantly linked to metabolic problems such as obesity, insulin resistance, and dyslipidemia. Sitagliptin, a DPP-4 inhibitor, may play a significant role in metabolic, inflammatory, and hormonal abnormalities in PCOS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This randomized clinical trial aimed to investigate the impact of sitagliptin on metabolic disturbances, hormonal abnormalities, and clinical outcomes in patients with PCOS. The study is registered on\n                      <jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>\n                      with an ID of (NCT05972928).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized controlled trial was conducted at Beni-Suef University Hospital, involving 80 women diagnosed with PCOS based on the Rotterdam criteria. Participants were equally allocated into either a sitagliptin group, receiving 100\u00a0mg daily, or a control group, with a follow-up period of 3\u00a0months. Changes in body weight served as the sole primary outcome of the study. Meanwhile, changes in BMI, HOMA-IR, lipid profile, and hormonal indicators, along with clinical improvements in infertility, hirsutism, acne, and menstrual irregularity, were evaluated as secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regarding the primary outcome, a highly significant reduction in body weight was observed within the sitagliptin group (p &amp;lt; 0.001). Similarly, secondary outcomes including BMI, HOMA-IR, DHEA, HbA1c, total and free testosterone, and LH levels, all demonstrated significant decreases (p &amp;lt; 0.05). Clinical secondary outcomes also showed potential improvements, with menstrual regularity increasing significantly (p = 0.006), alongside visible reductions in hirsutism (p = 0.006) and exploratory reduction in the infertility rates (p = 0.031), that needs further confirmation. Furthermore, the intervention was well-tolerated, as recorded side effects were both rare and mild in intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sitagliptin has potential impact on the hormonal, metabolic and clinical aspects of PCOS, and an exploratory effect on reproductive function. This makes it a potentially promising option for managing this complex condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT05972928,<\/jats:ext-link>\n                      identifier NCT05972928.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1822226","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:30Z","timestamp":1790661030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Ahmed E.","family":"Altyar","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University","place":["Jeddah, Saudi Arabia"]},{"name":"Pharmacy Program, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Y.","family":"Dessouky","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Cairo University Hospitals (Kasr Al Ainy), Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Abdallah","family":"Mohamed Salem","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba F.","family":"Salem","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian S.","family":"Boshra","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence","volume-title":"Therapeutic Advances in Endocrinology and Metabolism","author":"Abdalla","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1210\/jcem.85.7.6682","article-title":"A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain","volume":"85","author":"Asunci\u00f3n","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.22270\/jddt.v9i4-s.3261","article-title":"Sitagliptin recuperates oxidative stress and inflammatory cytokine expression in ovary of PCOS rats","volume":"9","author":"Carani","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdiacomp.2014.08.007","article-title":"Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial","volume":"29","author":"Chan","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"B5","article-title":"Current guidelines for diagnosing PCOS","volume-title":"Diagnostics","author":"Christ","year":"2023"},{"key":"B6","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"B7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11845-020-02320-5","article-title":"Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI","volume":"190","author":"Daneshjou","year":"2021","journal-title":"Ir. J. Med. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1210\/clinem\/dgz028","article-title":"Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome","volume":"105","author":"Devin","year":"2020","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"19","author":"Fauser","year":"2004","journal-title":"Hum. Reprod"},{"key":"B10","first-page":"56","article-title":"Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis","volume-title":"J. Cardiovasc. Thorac. Res","author":"Hallajzadeh","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12905-025-03787-z","article-title":"The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Womens Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57421","DOI":"10.12775\/jehs.2025.77.57421","article-title":"Comprehensive management of polycystic ovary syndrome: the role of metformin in addressing metabolic and endocrine dysregulation","volume":"77","author":"Ka\u017amierczak","year":"2025","journal-title":"J. Educ. Health Sport"},{"key":"B13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clinthera.2024.11.015","article-title":"Recent advances in individualized clinical strategies for polycystic ovary syndrome: evidence from clinical trials and emerging pharmacotherapies","volume":"47","author":"Moka","year":"2025","journal-title":"Clin. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102375","DOI":"10.1016\/j.tice.2024.102375","article-title":"A cross talk study on sitagliptin mediated reclamation on TGF \u03b2 signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet","volume":"88","author":"Nanda","year":"2024","journal-title":"Tissue Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.hgmx.2017.03.001","article-title":"Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: a pilot study","volume":"81","author":"Paredes","year":"2018","journal-title":"Rev. M\u00e9dica del Hosp. General M\u00e9xico"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e30351","DOI":"10.7759\/cureus.30351","article-title":"Insulin resistance in polycystic ovarian syndrome","volume":"14","author":"Purwar","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"592760","DOI":"10.1155\/2010\/592760","article-title":"Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)","volume":"2010","author":"Reis","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"100763","DOI":"10.1016\/j.repbio.2023.100763","article-title":"The effect of sitagliptin combined with rosiglitazone on autophagy and inflammation in polycystic ovary syndrome by regulating PI3K\/AKT\/mTOR and TLR4\/NF-\u03baB pathway","volume":"23","author":"Ren","year":"2023","journal-title":"Reprod. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e3750","DOI":"10.1002\/dmrr.3750","article-title":"Postbariatric surgery hypoglycemia: nutritional, pharmacological and surgical perspectives","volume":"40","author":"Rossini","year":"2024","journal-title":"Diabetes\/Metabolism Res. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcp.29912","article-title":"Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome","volume":"236","author":"Rostamtabar","year":"2021","journal-title":"J. Cell. Physiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3390\/ijms22073789","article-title":"Chronic low grade inflammation in pathogenesis of pcos","volume":"22","author":"Rudnicka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.18502\/ijml.v9i1.9085","article-title":"The effect of sitagliptin on inflammatory mediators in the ovary of rat with polycystic ovary syndrome","volume":"9","author":"Safaeian","year":"2022","journal-title":"Int. J. Med. Lab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","article-title":"Sitagliptin: a review in type 2 diabetes","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/jcm12041454","article-title":"Polycystic ovary syndrome: etiology, current management, and future therapeutics","volume":"12","author":"Singh","year":"2023","journal-title":"J. Clin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1273542","DOI":"10.3389\/fendo.2023.1273542","article-title":"Androgen excess: a hallmark of polycystic ovary syndrome","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13048-023-01299-8","article-title":"Dehydroepiandrosterone-induced polycystic ovary syndrome mouse model requires continous treatments to maintain reproductive phenotypes","volume":"16","author":"Wu","year":"2023","journal-title":"J. Ovarian Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s43032-020-00316-1","article-title":"Effect of three androgen indexes (FAI, FT, and TT) on clinical, biochemical, and fertility outcomes in women with polycystic ovary syndrome","volume":"28","author":"Zhang","year":"2021","journal-title":"Reprod. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s43032-022-01061-3","article-title":"Effects of sitagliptin on metabolic indices and hormone levels in polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"30","author":"Zhang","year":"2023","journal-title":"Reprod. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:33Z","timestamp":1790661033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1822226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1822226"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1822226","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1822226"}}